EU Business News: GSK Consumer Gets New Name, Navamedic Strikes Ipsen Deal, Enzymatica Optimistic After Tough Year
Round-up of the latest European consumer health business news: GSK reveals name for standalone consumer health business will be Haleon; Norways' Navamedic strikes a distribution deal with Ipsen for select GI OTC products; and Sweden's Enzymatica hopeful that changed consumer behaviors will help its sales rebound in 2022.
You may also be interested in...
The fourth session of the AESGP 58th Annual Meeting in Madrid, Spain, focused on the use of advertising for responsible self-care. GSK Consumer Healthcare's general manager for Northern Europe, Jonathan Workman, argued that responsible advertising should start with “what people need, what people want.” Supporting Workman’s case for prevention-focused advertising, IPG Heath’s Zahid Siddique drew on his experience as both a marketing expert and pharmacist to show how consumer health campaigns can have positive impact on people’s lives.
A round-up of the latest European consumer health business news: Norway's Orkla strengthens its supplements offering with acquisition of UK's Healthspan; Bayer makes investment commitment to German Consumer Health operation; and Ipsen strikes a deal to promote brands in the Baltics.
GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.